耀才团队: 恒指仍然维持500点上落格局
耀才证券研究部团队称,昨晚(9月1日)美股三大指数全线向上,ISM制造业指数连续第四个月上升报56,胜预期的54.9,科技股继续造好,苹果股价拆细後破顶,最多曾升逾4%见134.8美元,纳指及标普500指数再刷新历史新高。
港股ADR变动不大,市场仍然愿意高追有业绩支持之股份,导致新旧经济股个别发展,离岸人民币近日走强,中资金融股能否有所反弹成关键,大市短期仍会於25,000点至25,500关口上落。
焦点股份方面,蓝筹新贵药明生物(02269.HK)再遭大股东减持较上日收市价折让6.7%。而中生制药(01177.HK)亦有新药获首批并视同通过仿制药质量和疗效一致性评价,留意医药板块走势。
从技术上看,恒指昨日未能成功突破250天线,则出现大阴烛从高位回落,短线将会考验25,000点关口之支持。如前文所述,一日恒指仍徘徊於100天及250天线之间,即24,500点至25,800点内,後市仍缺乏明确方向。
(笔者为证监会持牌人)~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.